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inv(16)(p13q22) G- banding (left) - Courtesy Jean-Luc Lai and Alain Vanderhaegen; R- banding center bottom: - Courtesy Christiane 
Charrin, center top and FISH (top right) -Courtesy Pascale Cornillet-Lefebvre and Stephanie Struski; FISH (bottom right) - Courtesy 
Hossein Mossafa; commercial FISH probes, split in the inv(16). t(16;16)(p13;q22) G-banding - Courtesy Diane H. Norback, Eric B. 
Johnson, and Sara Morrison-Delap, UW Cytogenetic Services. 
Clinics and pathology 
Disease 
Acute non lymphoblastic leukaemia (ANLL); 
myelodysplastic syndromes (MDS) at times. 
Phenotype/cell stem origin 
Nearly pathognomonic of M4eo-ANLL (all M4eo share 
the 16q22 anomaly -see also below-, but not all 
16p13/16q22 are found in the M4eo subtype: i.e. this
anomaly, although mainly found in M4-ANLL  
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Patients with inv(16) usually correspond to the subclass of AML M4, with a specific abnormal eosinophil component and is considered as 
a distinct entity in correlation with these specific chromosomal abnormalities. These cases of AML M4 are referred as AML M4EO. In 
addition to the morphological features of AML M4 excess of monocytes), the bone marrow shows a variable number of eosinophils at all 
stages of maturation without significant maturation arrest. The most striking abnormalities involve the immature eosinophilic granules. 
Those are mainly evident at the promyelocyte and myelocyte stages. The abnormalities are not usually evident at later stages of 
maturation. These eosinophilic granules are often larger than those normally seen in immature eosinophils, purple-violet in color and in 
some cells are so dense that they obscure the cell morphology - Courtesy Georges Flandrin, CD-ROM AML/MDS G.Flandrin/ICG. 
TRIBVN 
.
with marked eosinophilia, may (rarely) been found i :
M2 or M5, M4 without eo, or in MDS; there are also 
known cases of chronic myelogenous leukaemia in 
blast crisis (BC-CML) with a M4 eo phenotype and 
inv(16); found at times in treatment related ANLL; 3 
cases of infant leukaemia so far described; note: CD2 
(T-cell marker) may be co-expressed 
Epidemiology. 
5-10% of ANLL, 20% of M4. 
Clinics 
CNS involvement is frequent, according to some 
authors, in particular at relapse. 
Cytology 
Most often: eosinophils > 5%, with large immature 
basophilic granules, NASCA+, in the bone marrow (but 
normal in blood: this M4 do not show the eo' 
characteristic in blood). 
Prognosis 
High CR rate; better prognosis than most other ANLL; 




May be overlooked, especially with R-banding; best 
seen without banding procedure ('giemsa') for some 
workers. 
Cytogenetics molecular 
With 16p13 probes: as a deletion within 16p13 often 
accompany the 16p13/16q22 rearrangement (in 20% of 
cases), the split signal may be lost. 
Additional anomalies 
None 2/3 of cases; +8, +22 in 15% each, del(7q), +2; 
apparently without prognostic significance. 
Variants 
Are known:  
1- t(16;16)(p13;q22); - del(16)(q22): may be associated 
with less typical phenotype and preceding MDS, older 
age, complex karyotype, worse prognosis;  
2- but also: translocations of 16q22 with various 
partners in: t(1;16)(p31-32;q22), t(3;16)(q21;q22), 
inv(16)(p13q22), t(16;16)(p13;q22), del(16)(q22) Huret JL 
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t(5;16)(q33;q22), associated with eosinophils 
anomalies. 





 c-MYH11 (16p13) in normal cells: PAC 1032E3 (top) and PAC 
1179J13 (below) - Courtesy Mariano Rocchi. 
Protein 
Contains a N-term ATPase head responsible for actin 
binding and mechanical movement, and a C-term long 
repeat of coil-coil domain to facilitate filament 





Subunit of the transcription factor complex CBF; CBFb 
by itself does not contain any DNA binding motif or
transcriptional activation domain, but forms a dimer 
with CBFa: --> transcription factor. 




5' CBFb - 3' MYH11; breakpoint in CBFB intron n°5 
and in MYH11 intron A (i.e. : 5) 
Transcript 
At least 8 different CBFb-MYH11 fusion transcripts 
have been described, transcript type A (with positins 
at nucleotides 495 and 1921 respectively) being found 
in about 90% of the patients; most breakpoints in 




N-term - the first 165 (or 133 in a few cases) amino 
acids of CBFb, removing only 17 or 22 amino acids  
fused to the tail of MYH11 C-term with its 
multimerization domain; also variable breakpoint in 
MYH11; identical fusion protein in the cases of 
RAEBT and BC-CML. 
Expression / Localisation 
Nuclear localisation. 
Oncogenesis 
The fusion protein seems both to diminuish the quantity 
of active CBF and to compete with it, there is 
accumulation of CBFb-MYH11/CBFa multimeres in 
the nucleus. 
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